VENUSREM — Venus Remedies Share News
0.000.00%
Last trade - 00:00- IN₹16.56bn
- IN₹15.76bn
- IN₹7.70bn
India's Venus Remedies up 3% on securing GMP certification from Kenya
Brief: Venus Remedies Secures Kenyan Gmp Certification For All Its Manufacturing Facilities In Baddi
India's Venus Remedies up 11% on marketing approval for cancer drug
Brief: Venus Remedies Gets Marketing Authorisation For Two Widely Used Cancer Drugs From Philippines And Iraq
India's Venus Remedies jumps 5% on getting UK marketing authorisation for cancer drug
Brief: Venus Remedies Secures Marketing Authorisation From UK MHRA For Cisplatin
India's Venus Remedies rises after Saudi GMP approval
Brief: Venus Remedies Awarded Saudi GMP Approval For All Its Production Facilities In Baddi
India's Venus Remedies rises on marketing approval for cancer drugs
Brief: Venus Remedies Gets Marketing Approval For Carboplatin In Uzbekistan And Docetaxel And Irinotecan In Palestine
Brief: India's Venus Remedies Dec-Quarter Consol Net Profit Falls
Brief: Venus Remedies Selected For Production Linked Incentive Scheme Of Govt Of India
Brief: Venus Remedies Posts Dec-Qtr Consol Net Profit
India's Venus Remedies hits near 5-month high after Cipla acquires co's drug
Brief: Venus Remedies Announces Sale Of Elores To Cipla In India
Brief: India's Venus Remedies June Quarter Loss Narrows
Brief: India's Venus Remedies Dec Qtr Loss Widens
Brief: India's Venus Remedies Gets Shareholders' Nod To Re-Appointment Manu Chaudhary As Joint MD
Brief: India's Venus Remedies Posts March Quarter Loss